Use of Technetium-99m-Labeled Methoxy-Isobutyl Isonitrile and Iodine 123-Labeled Phenyl-Methyl-Pentadecanoic Acid in the Diagnosis and Prognosis of Patients with Dilated Cardiomyopathy

Abstract:

The objective of this study is to assess perfusion and metabolic state of the left ventricular in patients with dilated cardiomyopathy (DCM) using scintigraphy with MIBI and BMIPP, as well as to develop the predictors of efficacy of cardiac resynchronization therapy (CRT). The study included 51 patients with DCM who underwent CRT. Correlation between the values of LV ESV after CRT and preoperative perfusion and metabolic defects sizes was detected. "Responders" and "non-responders" groups were significantly different from the perfusion and metabolic defects sizes. Myocardial perfusion-metabolic scintigraphy can be used as additional criteria for the selection of patients for CRT.

• Periodical: Advanced Materials Research (Volume 1084)
• Pages: 532-535
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.1084.532
• Online since: January 2015
• Authors: Yuri B. Lishmanov*, Konstantin V. Zavadovsky, Marina O. Gulya, Stanislav M. Minin, Denis I. Lebedev
• Keywords: Dilated Cardiomyopathy, Methoxy-Isobutyl Isonitrile, Phenyl-Methyl-Pentadecanoic Acid

References

[1] N. Tamaki, K. Morita, Y. Kuge, E. Tsukamoto, The role of fatty acids in cardiac imaging, J Nucl Med. 41 (2000) 1525-1534.

[2] F. Knapp, P. Franken, J. Kropp, Cardiac SPECT with iodine-123-labeled fatty acids: evaluation of myocardial viability with BMIPP, J Nucl Med. 36, 6 (1995) 1022-30.

[3] T.A. Manolio, K.L. Baughman, R. Rodeheffer, T.A. Pearson, J.D. Bristow, V.V. Michels, W.H. Abelmann, W.R. Harlan, Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop), Am J Cardiol. 69 (1992).

DOI: 10.1016/0002-9149(92)90901-a

[4] F.A. McAlister, J.A. Ezekowitz, N. Wiebe, B. Rowe, C. Spooner, E. Crumley, L. Hartling, T. Klassen, W. Abraham, Systematic review: cardiac resynchronization in patients with symptomatic heart failure, Ann. Intern. Med. 141. 5 (2004) 381-390.

DOI: 10.7326/0003-4819-141-5-200409070-00101

[5] J. Abdulla, J. Haarbo, L. Kober, C. Torp-Pedersen, Impact of implantable defibrillators and resynchronization therapy on outcome in patients with left ventricular dysfunction – a meta-analysis, Cardiology. 106 (2006) 249-255.

DOI: 10.1159/000093234

[6] D.J. Bradley, E.A. Bradley, K.L. Baughman, R.D. Berger, H. Calkins, S.N. Goodman, D.A. Kass, N.R. Powe, Cardiac resynchronization and death from progressive heart failure: a metaanalysis of randomized controlled trials, JAMA. 289 (2003) 730-740.

DOI: 10.1001/jama.289.6.730

[7] A.A. Sokolov, G.I. Martsinkevich, Electromechanical cardiac asynchronism and heart failure, Cardiologiya (in Russian). 45. 5 (2005) 85-91.

[8] C. Leckercq, D.A. Kass, Retiming the failing heart: principles and current clinical status of cardiac resynchronization, J Am Coll Cardiol. 16. 39 (2002) 194-201.

DOI: 10.1016/s0735-1097(01)01747-8

[9] W.T. Abraham, D.L. Hayes, Cardiac resynchronization therapy for heart failure, Circulation. 108 (2003) 2596-2603.

DOI: 10.1161/01.cir.0000096580.26969.9a

[10] K.V. Zavadovsky, A.N. Pankova, Scintigraphic assessment of the right ventricular dysfunction in patients with cardiac pulmonary thromboembolism, Meditsinskaya vizualizatsiya (in Russian). 3 (2009). 24-30.

[11] I. Matsunari, S. Fujino, J. Taki, J. Senma, T. Aoyama, T. Wakasugi, J. Hirai, T. Saga, K. Ichiyanagi, K. Hisada, Impaired fatty acid uptake in ischemic but viable myocardium identified by thallium-201 reinjection, Am Heart J. 131, 3 (1996).

DOI: 10.1016/s0002-8703(96)90523-2

[12] N. Inoue, N. Takahashi, T. Ishikawa, S. Sumita, T. Kobayashi, K. Matsushita, K. Matsumoto, M. Taima, M. Shimura, K. Uchino, K. Kimura, T. Inoue, S. Umemura, Reverse perfusion-metabolism mismatch predicts good prognosis in patients undergoing cardiac resynchronization therapy: a pilot study, Circ J. 71, 1 (2007).

DOI: 10.1253/circj.71.126